To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Clinical trial NCT06898060 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06898060
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-01
- Primary completion
- 2027-05-01
- Enrollment
- 282
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.